title: Prevalence and clinical correlates of bronchoreversibility in severe emphysema.
abstract: Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains controversial. We hypothesised that an emphysematous phenotype of COPD would be associated with decreased bronchoreversibility. 544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. Participants underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of emphysema by computed tomography. Mean baseline forced expiratory volume in 1 s (FEV(1)) in this patient population is 24% predicted. 22.2% of patients demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few patients (0.37%) had bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less emphysema. 64% of patients demonstrated large (> or =400 mL) changes in forced vital capacity (FVC). In a severe emphysema population, bronchoreversibility as defined by change in FEV(1) is infrequent, varies over time, and is more common in males and those with less severe emphysema. Improvements in FVC, however, were demonstrated in the majority of patients.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109-0360, USA. mrking@umich.edu
authors.forename: M K
authors.initials: MK
authors.lastname: Han
authors.forename: R
authors.initials: R
authors.lastname: Wise
authors.forename: J
authors.initials: J
authors.lastname: Mumford
authors.forename: F
authors.initials: F
authors.lastname: Sciurba
authors.forename: G J
authors.initials: GJ
authors.lastname: Criner
authors.forename: J L
authors.initials: JL
authors.lastname: Curtis
authors.forename: S
authors.initials: S
authors.lastname: Murray
authors.forename: A
authors.initials: A
authors.lastname: Sternberg
authors.forename: G
authors.initials: G
authors.lastname: Weinman
authors.forename: E
authors.initials: E
authors.lastname: Kazerooni
authors.forename: A P
authors.initials: AP
authors.lastname: Fishman
authors.forename: B
authors.initials: B
authors.lastname: Make
authors.forename: E A
authors.initials: EA
authors.lastname: Hoffman
authors.forename: Z
authors.initials: Z
authors.lastname: Mosenifar
authors.forename: F J
authors.initials: FJ
authors.lastname: Martinez
mesh_terms: D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004646:Emphysema / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D009330:Nebulizers and Vaporizers; D010641:Phenotype; D011446:Prospective Studies; D011788:Quality of Life; D012129:Respiratory Function Tests; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed
chemical_list: D001993:Bronchodilator Agents; D000420:Albuterol